Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2013

Florida Hospital to Evaluate VTT’s Alzheimer’s Biomarker Assay

  • VTT Technical Research Centre of Finland is taking an important step toward advancing its Alzheimer’s disease biomarker by collaborating with the Florida Hospital Neuroscience Institute to evaluate screening, diagnostic, and prognostic potential of the biomarker assay and utilize it to specifically target which types of precautions to take when approaching early stages of the disease.

    A serum biochemical signature that predicts progression to Alzheimer’s disease was previously developed by scientists from VTT and the University of Eastern Finland. As a result of the collaboration, VTT was able to develop a biomarker assay, according to the company.

    Earlier this week, VTT announced partnership in a consortium focused on creating new diagnostic and bioinformatics tools for psychotic disorders with the overall objective to identify, prioritize, and evaluate multi-modal blood and neuroimaging biomarkers that have diagnostic potential for prediction and monitoring psychotic disorders and associated metabolic comorbidities.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »